相关实验视频

Updated: Jun 25, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

液立基因因诱导肺状细胞癌的细胞周期停止和细胞亡

Yaqi Liu¹, Yixiao Wang², Yiran Yang¹

¹Department of Traditional Chinese Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.

Cell biochemistry and biophysics

|May 22, 2024

概括

液基宁 (LQ) 通过诱导细胞循环停止和亡来抑制肺状细胞癌 (LSCC) 的生长. 这种天然化合物使PI3K/AKT/mTOR通路失活,为LSCC提供了潜在的治疗策略.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

液化基因素 (LQ),一种来自Glycyrrhiza uralensis Fisch的二黄,在各种癌症中表现出抗瘤特性.
它在肺状细胞癌 (LSCC) 中的特定作用和机制需要阐明.

研究的目的:

研究LQ对LSCC的抗癌作用.
探索潜在的分子机制,特别是PI3K/AKT/mTOR通路.

主要方法:

在体外:MTT,殖民地形成试验和LSCC细胞系的流细胞计 (SK-MES-1,NCI-H520).
在体内:裸体小鼠模型中的瘤生长抑制.
对PI3K/AKT/mTOR通路蛋白质的西部斑点分析.
使用 LY294002 (PI3K 抑制剂) 的药理抑制.

主要成果:

在剂量和时间上,LQ显著抑制了LSCC细胞的增殖和活力.
LQ诱导的G2/M细胞周期停止,细胞亡和线粒体膜潜在损失.
在体内,LQ抑制了瘤生长,并降低了酸化PI3K,AKT和mTOR水平.
LY294002预治疗逆转了LQ诱导的影响,证实了途径的参与.

结论:

液化素有效抑制肺状细胞癌的进展.
通过非激活PI3K/AKT/mTOR信号通路,LQ通过诱导细胞周期停止和细胞亡来发挥其抗癌作用.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.细胞循环的细胞周期液态基因因的存在肺状细胞癌是肺的状细胞癌.在PI3K/AKT/mTOR中使用.

更多相关视频

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...